{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:20:57Z","timestamp":1791897657661,"version":"4.3.4"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG26757"],"award-info":[{"award-number":["AG26757"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009507","name":"Stein Institute for Research on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023741","name":"Center for Healthy Aging at the University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023741","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012424","name":"UCSD School of Medicine Summer Research Training Fellowship","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012424","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Elizabeth Keadle"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity and produce significant weight loss. However, concerns have emerged about potential loss of skeletal muscle mass (SMM) with pharmacologic weight reduction, particularly in older adults at risk for sarcopaenia. The effects of GLP-1 RA therapy on SMM among patients participating in intensive cardiac rehabilitation (ICR) remain incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A retrospective cohort study of 468 patients enrolled in a structured Pritikin ICR programme at UC San Diego Health between 2017 and 2024 was performed. At programme initiation, 67 patients were taking GLP-1 RAs with a median duration of 231 days (IQR 144\u2013400). Body composition was assessed using bioelectrical impedance analysis at baseline and programme completion. Outcomes included SMM and fat mass (FM). Multivariable regression models adjusted for age, sex, baseline body mass index (BMI), diabetes status, and baseline fitness (measured in metabolic equivalents of tasks [METs]). Both groups improved in METs with ICR (P &amp;lt; 0.001). At baseline, patients on GLP-1 RAs had higher BMI and percent FM compared with non-users, but no differences were observed in SMM. In adjusted analyses, GLP-1 RA use was not associated with significantly different per cent change in SMM from baseline to ICR programme completion compared with no GLP-1 RA use (\u03b2 = 0.62%, 95% CI \u22120.62 to 1.86; P = 0.326). Similarly, there was no significant between-group difference in per cent change in FM (\u03b2 = 3.01%, 95% CI \u22121.64 to 7.66; P = 0.204).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1 RA use during ICR was not associated with significantly different SMM changes after adjustment for measured covariates. These findings support the integration of GLP-1 based pharmacotherapy with structured exercise programmes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwag279","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:35:00Z","timestamp":1779190500000},"page":"2665-2674","source":"Crossref","is-referenced-by-count":0,"title":["Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0637-4291","authenticated-orcid":false,"given":"Ian","family":"Jennings","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, UC San Diego School of Medicine , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-9656","authenticated-orcid":false,"given":"Kristine","family":"Ly","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, UC San Diego School of Medicine , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5133-6579","authenticated-orcid":false,"given":"Mariam","family":"Marooki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, UC San Diego School of Medicine , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0603-4547","authenticated-orcid":false,"given":"Marissa","family":"Dzotsi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, UC San Diego School of Medicine , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2122-6364","authenticated-orcid":false,"given":"Gavin","family":"McLaren","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, UC San Diego School of Medicine , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8179-0619","authenticated-orcid":false,"given":"Raphael E","family":"Cuomo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, UC San Diego School of Medicine , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-8881","authenticated-orcid":false,"given":"Shady","family":"Abohashem","sequence":"additional","affiliation":[{"name":"Cardiology Department and Cardiovascular Imaging Research Center, Harvard University Medical School and Massachusetts General Hospital , Boston, MA ,","place":["USA"]},{"name":"Division of Outcomes Research, Harvard University Medical School and Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0684-0655","authenticated-orcid":false,"given":"Pam R","family":"Taub","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, UC San Diego School of Medicine , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026101219574771900_zwag279-B1","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026101219574771900_zwag279-B2","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1007\/s13300-018-0524-z","article-title":"Liraglutide and glycaemic outcomes in the LEADER trial","volume":"9","author":"Zinman","year":"2018","journal-title":"Diabetes Ther"},{"key":"2026101219574771900_zwag279-B3","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026101219574771900_zwag279-B4","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026101219574771900_zwag279-B5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026101219574771900_zwag279-B6","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"key":"2026101219574771900_zwag279-B7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: a meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"2026101219574771900_zwag279-B8","doi-asserted-by":"crossref","first-page":"E677","DOI":"10.1152\/ajpendo.00446.2012","article-title":"Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose","volume":"304","author":"Burmeister","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026101219574771900_zwag279-B9","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"2026101219574771900_zwag279-B10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"2026101219574771900_zwag279-B11","article-title":"Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: a model-based meta-analysis of placebo-controlled trials","volume":"13","author":"Guo","year":"2025","journal-title":"Obes Pillars"},{"key":"2026101219574771900_zwag279-B12","article-title":"Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis","volume":"35","author":"Vosoughi","year":"2022","journal-title":"Obes Med"},{"key":"2026101219574771900_zwag279-B13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026101219574771900_zwag279-B14","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"2026101219574771900_zwag279-B15","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jgs.16372","article-title":"Sarcopenia definition: the position statements of the sarcopenia definition and outcomes consortium","volume":"68","author":"Bhasin","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"2026101219574771900_zwag279-B16","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jcsm.13445","article-title":"Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial","volume":"15","author":"Pandey","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026101219574771900_zwag279-B17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026101219574771900_zwag279-B18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026101219574771900_zwag279-B19","first-page":"S3","article-title":"Tirzepatide achieves significant weight loss without adverse effects on muscle composition (SURPASS-3 MRI)","volume":"66","author":"Linge","year":"2023","journal-title":"Diabetologia"},{"key":"2026101219574771900_zwag279-B20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Rodr\u00edguez \u00c1. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026101219574771900_zwag279-B21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/cells11010160","article-title":"Multifactorial mechanism of sarcopenia and sarcopenic obesity. Role of physical exercise, microbiota and myokines","volume":"11","author":"Bilski","year":"2022","journal-title":"Cells"},{"key":"2026101219574771900_zwag279-B22","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1161\/CIRCULATIONAHA.123.064071","article-title":"Sarcopenia and cardiovascular diseases","volume":"147","author":"Damluji","year":"2023","journal-title":"Circulation"},{"key":"2026101219574771900_zwag279-B23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","article-title":"A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans","volume":"34","author":"Sargeant","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2026101219574771900_zwag279-B24","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2169\/internalmedicine.3259-23","article-title":"Clinical efficacy and body composition changes with sodium glucose cotransporter 2 inhibitor\/glucagon-like peptide-1 antagonist combination therapy in patients with type 2 diabetes mellitus-associated nonalcoholic fatty liver disease","volume":"63","author":"Ishikawa","year":"2024","journal-title":"Intern Med"},{"key":"2026101219574771900_zwag279-B25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4239\/wjd.v9.i8.138","article-title":"Exercise and glucagon-like peptide-1: does exercise potentiate the effect of treatment?","volume":"9","author":"Hamasaki","year":"2018","journal-title":"World J Diabetes"},{"key":"2026101219574771900_zwag279-B26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1249\/JSR.0b013e31825dabb8","article-title":"Resistance training is medicine: effects of strength training on health","volume":"11","author":"Westcott","year":"2012","journal-title":"Curr Sports Med Rep"},{"key":"2026101219574771900_zwag279-B27","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s40279-020-01309-5","article-title":"The benefits of strength training on musculoskeletal system health: practical applications for interdisciplinary care","volume":"50","author":"Maestroni","year":"2020","journal-title":"Sports Med"},{"key":"2026101219574771900_zwag279-B28","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1519\/JSC.0000000000003230","article-title":"Resistance training for older adults: position statement from the national strength and conditioning association","volume":"33","author":"Fragala","year":"2019","journal-title":"J Strength Cond Res"},{"key":"2026101219574771900_zwag279-B29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/bjsports-2024-108947","article-title":"Impact of resistance training on cardiometabolic health-related indices in patients with type 2 diabetes and overweight\/obesity: a systematic review and meta-analysis of randomised controlled trials","volume":"59","author":"Al-Mhanna","year":"2025","journal-title":"Br J Sports Med"},{"key":"2026101219574771900_zwag279-B30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0025-6196(11)60548-X","article-title":"Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease","volume":"84","author":"Lavie","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"2026101219574771900_zwag279-B31","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehq236","article-title":"Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training: key components of the position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation","volume":"31","author":"European Association of Cardiovascular Prevention and Rehabilitation Committee for Science Guidelines","year":"2010","journal-title":"Eur Heart J"},{"key":"2026101219574771900_zwag279-B32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11886-021-01482-7","article-title":"Cardiac rehab in the COVID era and beyond: mHealth and other novel opportunities","volume":"23","author":"Epstein","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"2026101219574771900_zwag279-B33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/HCR.0000000000000903","article-title":"Comparison of traditional and intensive cardiac rehabilitation on dietary behavior and clinical risk factor outcomes: secondary analysis research","volume":"45","author":"Rasmussen","year":"2025","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"2026101219574771900_zwag279-B34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3233\/CH-242134","article-title":"Tirzepatide and exercise training in obesity","volume":"87","author":"Bagherzadeh-Rahmani","year":"2024","journal-title":"Clin Hemorheol Microcirc"},{"key":"2026101219574771900_zwag279-B35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/14656566.2021.2019707","article-title":"Adding liraglutide to diet and exercise to maintain weight loss - is it worth it?","volume":"23","author":"Doggrell","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"2026101219574771900_zwag279-B36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/HCR.0000000000000700","article-title":"Benefits of the first Pritikin outpatient intensive cardiac rehabilitation program","volume":"42","author":"Racette","year":"2022","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"2026101219574771900_zwag279-B37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11886-019-1104-1","article-title":"Intensive cardiac rehabilitation: an underutilized resource","volume":"21","author":"Freeman","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2026101219574771900_zwag279-B38","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.3390\/nu17223503","article-title":"Age-related anabolic resistance: nutritional and exercise strategies, and potential relevance to life-long exercisers","volume":"17","author":"P\u00e9rez-Castillo","year":"2025","journal-title":"Nutrients"},{"key":"2026101219574771900_zwag279-B39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/gerona\/glab111","article-title":"Effect of aerobic or resistance exercise, or both, on intermuscular and visceral fat and physical and metabolic function in older adults with obesity while dieting","volume":"77","author":"Waters","year":"2022","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026101219574771900_zwag279-B40","first-page":"863","article-title":"Skeletal muscle dysfunction advancing age","volume":"138","author":"Pardeep","year":"1979","journal-title":"Clin Sci"},{"key":"2026101219574771900_zwag279-B41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"2026101219574771900_zwag279-B42","doi-asserted-by":"crossref","first-page":"482","DOI":"10.4093\/dmj.2020.0277","article-title":"Computed tomography-derived myosteatosis and metabolic disorders","volume":"45","author":"Miljkovic","year":"2021","journal-title":"Diabetes Metab J"},{"key":"2026101219574771900_zwag279-B43","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/309570","article-title":"Intermuscular fat: a review of the consequences and causes","volume":"2014","author":"Addison","year":"2014","journal-title":"Int J Endocrinol"},{"key":"2026101219574771900_zwag279-B44","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/jcsm.12834","article-title":"Adverse muscle composition predicts all-cause mortality in the UK Biobank imaging study","volume":"12","author":"Linge","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026101219574771900_zwag279-B45","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13677","article-title":"The effects of glucagon-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review","volume":"16","author":"Old","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026101219574771900_zwag279-B46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026101219574771900_zwag279-B47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11914-022-00744-9","article-title":"Weight loss interventions and skeletal health in persons with diabetes","volume":"20","author":"Zhao","year":"2022","journal-title":"Curr Osteoporos Rep"},{"key":"2026101219574771900_zwag279-B48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clnu.2011.04.001","article-title":"Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population","volume":"30","author":"Ling","year":"2011","journal-title":"Clin Nutr"},{"key":"2026101219574771900_zwag279-B49","doi-asserted-by":"crossref","DOI":"10.1080\/19932820.2020.1741904","article-title":"Evaluating altered hydration status effectiveness body composition analysis using bioelectrical impedance analysis","volume":"15","author":"Ugras","year":"2020","journal-title":"Libyan J Med"},{"key":"2026101219574771900_zwag279-B50","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41430-020-00839-5","article-title":"Comparison of body composition assessment across body mass index categories by two multifrequency bioelectrical impedance analysis devices and dual-energy X-ray absorptiometry in clinical settings","volume":"75","author":"Lahav","year":"2021","journal-title":"Eur J Clin Nutr"},{"key":"2026101219574771900_zwag279-B51","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1519\/JSC.0000000000003360","article-title":"The effects of caffeine and Citrus aurantium on performance during repeated maximal anaerobic exercise bouts in habitual caffeine users","volume":"35","author":"McLester","year":"2021","journal-title":"J Strength Cond Res"},{"key":"2026101219574771900_zwag279-B52","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/jpen.1994","article-title":"The comparison of segmental multifrequency bioelectrical impedance analysis and dual-energy X-ray absorptiometry for estimating fat free mass and percentage body fat in an ambulatory population","volume":"45","author":"Hurt","year":"2021","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2026101219574771900_zwag279-B53","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1491931","article-title":"Reliability, biological variability, and accuracy of multi-frequency bioelectrical impedance analysis for measuring body composition components","volume":"11","author":"Looney","year":"2024","journal-title":"Front Nutr"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag279\/68354622\/zwag279.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/14\/2665\/68354622\/zwag279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/33\/14\/2665\/68354622\/zwag279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:58:01Z","timestamp":1791849481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/33\/14\/2665\/8688935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":53,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag279","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,5,21]]}}}